Reviewed by: One Very Tired Tumor Microenvironment
"Ordered the neoadjuvant radioimmunotherapy bundle after hearing cisplatin wasn't an option. Delivery was prompt - nivolumab showed up every two weeks like clockwork, and the 50.4 Gy of radiation came in 28 well-portioned fractions. Installation required a full surgical team (radical cystectomy, no less). 39% of tumors completely vanished. Would absolutely recommend to cisplatin-ineligible friends. Only four stars because the waiting period before surgery felt like forever."
If that fictional five-star review sounds suspiciously optimistic, buckle up - because the real data from the RACE-IT trial is just as compelling.
The Battlefield: When Cisplatin Isn't in Your Arsenal
Muscle-invasive bladder cancer (MIBC) is one of the most aggressive opponents on the oncology chessboard. The standard opening move has long been neoadjuvant cisplatin-based chemotherapy before radical cystectomy - a proven strategy that softens the tumor before surgeons go in for the kill. But here's the tactical problem: roughly half of all MIBC patients can't tolerate cisplatin due to kidney issues, hearing loss, or poor overall fitness (Galsky et al., 2011). That's like sending an army into battle and realizing half your troops don't have weapons.
For years, these cisplatin-ineligible patients went straight to surgery with no neoadjuvant warm-up act. The RACE-IT trial asked a bold tactical question: what if we sent in an entirely different strike team?
The Game Plan: Radiation Meets Immune Checkpoint Blockade
The RACE-IT trial, led by Sebastian Schmid and colleagues across multiple German centers, deployed a two-pronged offensive in 33 patients with locally advanced bladder cancer (cT3-4) who couldn't receive cisplatin (Schmid et al., 2026). The strategy: four cycles of nivolumab (a PD-1 checkpoint inhibitor) every two weeks, combined with radiation therapy targeting the bladder and pelvic lymph nodes. After this coordinated assault, patients underwent radical cystectomy within 11 to 15 weeks.
The underlying tactical logic is genuinely elegant. Radiation doesn't just blast tumor cells - it causes immunogenic cell death, essentially forcing cancer cells to spill their molecular secrets onto the battlefield. These released tumor antigens then serve as targeting coordinates for the immune system, which has been simultaneously unleashed by nivolumab blocking the PD-1 "stand down" signal. Think of radiation as the reconnaissance team blowing the enemy's cover while immunotherapy calls in the air strike (Schmid et al., 2020).
The Scoreboard: Numbers That Actually Impress
The trial hit its primary feasibility endpoint (P = .038), with 87% of patients completing the full treatment protocol on schedule. But the secondary endpoints are where it gets really interesting:
- Pathologic complete response (ypT0 ypN0): 39% - meaning in over a third of patients, surgeons opened them up and found... nothing. The tumor had been completely eliminated before the scalpel even touched it.
- Downstaging to non-muscle-invasive disease: 58% - nearly six in ten patients saw their cancer retreat from "locally advanced" to a far less threatening position.
For context, the landmark NIAGARA trial - which combined durvalumab with cisplatin-based chemotherapy in cisplatin-eligible patients - achieved a 42% pCR rate (Powles et al., 2024). RACE-IT's 39% in cisplatin-ineligible patients, using a completely different playbook, is a remarkably competitive showing.
Why This Matters: The Cisplatin-Ineligible Gap is Closing
The commentary by Singh and Srivastav in European Urology Oncology highlights exactly why RACE-IT matters in the broader strategic landscape (Singh & Srivastav, 2026). We're witnessing a genuine paradigm shift. The KEYNOTE-905 trial recently showed that enfortumab vedotin plus pembrolizumab can achieve a staggering 57% pCR rate in cisplatin-ineligible patients. Add RACE-IT's radioimmunotherapy approach to the mix, and suddenly these historically underserved patients have multiple viable counter-offensives to choose from.
The field is moving fast. Neoadjuvant immunotherapy strategies - whether combined with chemotherapy, radiation, or antibody-drug conjugates - are rapidly becoming standard options rather than experimental longshots (Cathomas et al., 2025).
The Next Move
RACE-IT is a phase 2 trial with 33 patients, so let's not crown it champion just yet. Larger, randomized trials will need to confirm whether this radiation-immunotherapy combo genuinely outperforms other approaches. Questions about optimal radiation dosing, immunotherapy sequencing, and long-term survival remain open. But as an opening gambit for cisplatin-ineligible patients, the strategy is sound, the safety profile checks out, and the early results suggest this team has real championship potential.
The bladder cancer treatment playbook just got a lot thicker - and for the patients who've been stuck on the sidelines without cisplatin, that's the kind of roster expansion worth celebrating.
References
-
Schmid SC, Jahnen M, Schiller K, et al. Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT). Eur Urol Oncol. 2026. DOI: 10.1016/j.euo.2026.02.019
-
Singh N, Srivastav M. Re: Sebastian C. Schmid, Matthias Jahnen, Kilian Schiller, et al. Eur Urol Oncol. 2026. PMID: 42000299. DOI: 10.1016/j.euo.2026.03.023
-
Schmid SC, Koll FJ, Rödel C, et al. Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT). BMC Cancer. 2020;20(1):7. PMID: 31900121. DOI: 10.1186/s12885-019-6503-6
-
Powles T, Valderrama BP, Gupta S, et al. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer (NIAGARA). N Engl J Med. 2024. DOI: 10.1056/NEJMoa2408154
-
Cathomas R, et al. Neoadjuvant immunotherapy for muscle-invasive bladder cancer: a 2025 update. Immunotherapy. 2025;17(6). PMID: 40329651. DOI: 10.1080/1750743X.2025.2501929
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.